Abstract
To test the potential role of H19 as a tumour suppressor gene we have examined its expression and DNA methylation in Wilms' tumours (WTs). In most WTs (18/25), H19 RNA was reduced at least 20–fold from fetal kidney levels. Of the expression–negative tumours ten retained 11p15.5 heterozygosity: in nine of these, H19 DNA was biallelically hypermethylated and in two cases hypermethylation locally restricted to H19 sequences was also present in the non–neoplastic kidney parenchyma. IGF2 mRNA was expressed in most but not all WTs and expression patterns were consistent with IGF2/H19 enhancer competition without obligate inverse coupling. These observations implicate genetic and epigenetic inactivation of H19 in Wilms' tumorigenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pachnis, V., Brannan, C.I. & Tilghman, S.M. The structure and expression of a novel gene activated In early mouse embryogenesis. EMBO J. 7, 673–681 (1988).
Wiles, M.V. Isolation of differentially expressed human cDNA clones: similarities between mouse and human embryonal stem cell differentiation. Development 104, 403–413 (1988).
Poirier, F. et al. The murine H19 gene is activated during embryonic stem cell differentiation in vitro and at the time of implantation in the developing embryo. Development 113, 1105–1114 (1992).
Rachmllewitz, J. et al. Transcription of the H19 gene in differentiating cytotrophoblasts from human placenta. Molec. Rep. Dev. 321, 196–202 (1992).
Han, D.K. & Liau, G. Identification and characterization of developmentally regulated genes in vascular smooth muscle cells. Circ. Res. 71, 711–719 (1992).
Hao, Y., Crenshaw, T., Moulton, T., Newcomb, E. & Tycko, B. Tumour-suppressor activity of H19 RNA. Nature 365, 764–767 (1993).
Goshen, R. et al. The expression of the H19 and IGF2 genes during human embryogenesis and placental development. Molec. Rep. Dev. 34, 374–379 (1993).
Lustig, O. et al. The expression of the imprinted H19 gene in the human fetus. Mol Rep. Dev. (in the press).
Brannan, C.I., Dees, E.C., Ingram, R.S. & Tilghman, S.M. The product of the H19 gene may function as an RNA. Molec. cell. Biol. 10, 28–36 (1990).
Brockdorff, N. et al. The product of the mouse Xist gene is a 15 Kb inactive-X-specific transcript containing no conserved ORF and located in the nucleus. Cell 71, 515–526 (1992).
Bartolomei, M.S., Zemel, S. & Tilghman, S.M. Parental imprinting of the mouse H19 gene. Nature 351, 153–155 (1991).
Zhang, Y. & Tycko, B. Monoallelic expression of the human H19 gene. Nature Genet. 1, 40–44 (1992).
Rachmilewitz, J. et al. Parental imprinting of the human H19 gene. FEBS Lett. 309, 25–28 (1992).
Rainier, S. et al. Relaxation of Imprinted genes in human cancer. Nature 362, 747–749 (1993).
Zhang, Y. et al. Imprinting of human H19: allele-specific CpG methylation, loss of the active allele In Wilms' tumor and potential for somatic allele switching. Am. J. hum. Genet. 53, 113–124 (1993).
Bartolomei, M.S., Webber, A.L., Brunkow, M.E. & Tilghman, S.M. Epigenetic mechanisms underlying the imprinting of the mouse H19 gene. Genes Devel. 7, 1663–1673 (1993).
Ferguson-Smith, A.C., Sasaki, H., Cattanach, B.M. & Surani, M.A. Parentalorigin-specific epigenetlc modification of the mouse H19 gene. Nature 362, 751–755 (1993).
Tycko, B. Imprinting: mechanism and role in human pathology. Am. J. Pathol. 144, 431–443 (1994).
Brunkow, M.E. & Tilghman, S.M. Ectopic expression of the H19 gene in mice causes prenatal lethality. Genes Dev. 5, 1092–1101 (1991).
Ogawa, O. et al. Relaxation of insulin-like growth factor II gene imprinting Implicated in Wilms' tumour. Nature 362, 749–751 (1993).
Reeve, A.E., Eccles, M.R., Wilkins, R.J., Bell, G.I. & Millow, L.J. Expression of insulin-like growth factor-II transcripts in Wilms' tumour. Nature 317, 258–260 (1985).
Scott, J. et al. Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues. Nature 317, 260–262 (1985).
Han, O.K. & Liau, G. Identification and characterization of developmentally regulated genes in vascular smooth muscle cells. Circ. Res. 71, 711–719 (1992).
Henry, I. et al. Molecular definition of the 11p15.5 region involved in Beckwith-Weidermann syndrome and In predispostion to adrenocortical carcinoma. Hum. Genet. 81, 273–277 (1989).
Littte, M.H., Clarke, J., Byrne, J., Dunn, R. & Smith, P.J. Allelic loss on chromosome 11p is a less frequent event in bilateral than in unilateral Wilms' tumours. Eur. J. Cancer 28A, 1876–1880 (1992).
Weksberg, R., Shen, D.R., Fei, Y.L., Song, Q.L. & Squire, J. Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome. Nature Genet. 5, 143–150 (1993).
Chao, L.-Y. et al. Genetic mosaicism In normal tissues of Wilms' tumor patients. Nature Genet. 3, 127–131 (1993).
Yandell, D.W., Dryja, T.P. & Little, J.B. Somatic mutations at a heterozygous autosomal locus in human cancer cells occur more frequently by allele loss than by intragenic structural alterations. Som. Cell molec. Genet. 12, 255–263 (1986).
Klinedinst, D.K. & Drinkwater, N.R. Reduction to homozygosity is the predominant spontaneous mutational event in cultured human lymphoblastoid cells. Mutat. Res. 250, 365–374 (1991).
Coppes, M.J. et al. Loss of heterozygosity mapping in Wilms tumor indicates the involvement of three distinct regions and a limited role for nondisjunction or mitotic recombination. Genes Chrom. Cancer 5, 326–334 (1992).
Tartof, K. & Henikoff, S. Trans-sensing effects from Drosophila to humans. Cell 65, 201–203 (1991).
Fidler, A.E., Maw, M.A., Eccles, M.R. & Reeve, A.E. Trans-sensing hypothesis for origin of Beckwith-Wiedemann syndrome. Lancet 339, 243 (1992).
Feinberg, A.P. & Vogelstein, B. Hypomethylation distinguishes genes of, some human cancers from their normal counterparts. Nature 301, 89–91 (1983).
Haselbacher, G.K., Irminger, J-C., Zapf, J., Ziegler, W.H. & Humbel, R.E. Insulin-like growth factor II in human adrenal pheochromocytomas and Wilms tumors: Expression at the mRNA and protein level. Proc. natn. Acad. Sci. U.S.A. 84, 1104–1106 (1987).
Baccarini, P., Florentino, M., DErrico, A., Mancini, A.M. & Grigioni, W.F. Detection of anti-sense transcripts of the Insulin-like growth factor-2 gene in Wilms tumor. Am. J. Pathol. 143, 1535–1542 (1993).
Rastinejad, F., Conboy, M.J., Rando, T.A. & Blau, H.M. Tumor suppression by RNA from the 3′ untranslated region of α-tropomyosin. Cell 75, 1107–1118 (1993).
Polymeropoulos, M.H., Xiao, H., Rath, D.S. & Merril, C.R. Tetranucleotide repeat polymorphism at the human tyroslne hydroxylase gene (TH). Nucl. Adds Res. 19, 3753 (1991).
Tadokoro, K., Fujii, H., Inoue, T. & Yamada, M. Polymerase chain reaction (PCR) for detection of Apal polymorphism at the insulin like growth factor II gene (IGF2). Nucl. Acids Res. 19, 6967 (1991).
Riggins, G.J., Lokey, L.K. & Warren, S.T. CGG repeat polymorphism at the c-Ha-ras oncogene locus. Hum. molec. Genet. 1, 775 (1992).
Feinberg, A.P. & Vogelstein, B. Hypomethylation of ras oncogenes in primary human cancers. Biochem. Biophys. Res. Comm. 111, 47–54 (1983).
Dull, T.J., Gray, A., Hayflick, J.S. & Ullrich, A. Insulin-like growth factor II precursor gene organization in relation to insulin gene family. Nature 310, 777–781.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moulton, T., Crenshaw, T., Hao, Y. et al. Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nat Genet 7, 440–447 (1994). https://doi.org/10.1038/ng0794-440
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ng0794-440
This article is cited by
-
Cancer predisposition signaling in Beckwith-Wiedemann Syndrome drives Wilms tumor development
British Journal of Cancer (2024)
-
Genome-wide analysis of constitutional DNA methylation in familial melanoma
Clinical Epigenetics (2020)
-
Inhibition of mTORC1 by lncRNA H19 via disrupting 4E-BP1/Raptor interaction in pituitary tumours
Nature Communications (2018)
-
K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth
Medical Oncology (2017)
-
Constitutional epimutation as a mechanism for cancer causality and heritability?
Nature Reviews Cancer (2015)